PeptiDream Inc. (4587.T)
| Previous close | 2,022.00 |
| Open | 2,021.00 |
| Bid | 2,095.50 x 0 |
| Ask | 2,098.50 x 0 |
| Day's range | 2,006.00 - 2,121.00 |
| 52-week range | 1,039.00 - 2,549.00 |
| Volume | |
| Avg. volume | 868,832 |
| Market cap | 271.788B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 89.39 |
| EPS (TTM) | 23.46 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 June 2011 |
| 1y target est | 2,700.00 |
Business WirePeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
KAWASAKI, Japan, April 30, 2024--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG ("hereinafter Novartis") (NYSE: NVS). Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS®") technology to identify and optimize novel macrocyclic pepti
Business WirePeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates
KAWASAKI, Japan, September 20, 2023--Combining the PeptiDream's expertise in the field of peptide-RI conjugates, with Genentech's powerful development and commercialization capabilities.
Business WireAstellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders
TOKYO & KAWASAKI, Japan, July 25, 2023--PeptiDream and Astellas plan to combine PeptiDream's peptide discovery technology with Astellas' capabilities to discover next-gen protein degraders.
